UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 20,979 Shares of ICU Medical, Inc. $ICUI

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 26.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,442 shares of the medical instruments supplier’s stock after selling 20,979 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.23% of ICU Medical worth $8,568,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ICUI. Allworth Financial LP bought a new position in ICU Medical during the second quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of ICU Medical in the 4th quarter worth about $32,000. Public Employees Retirement System of Ohio purchased a new stake in shares of ICU Medical during the 2nd quarter valued at about $51,000. Covestor Ltd raised its position in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 126 shares in the last quarter. Finally, Strs Ohio lifted its holdings in shares of ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on ICUI shares. KeyCorp lifted their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Needham & Company LLC lifted their target price on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, BTIG Research boosted their target price on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $192.80.

Insider Activity

In other ICU Medical news, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the sale, the vice president owned 17,062 shares in the company, valued at $3,093,852.46. This trade represents a 24.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Virginia Sanzone sold 4,856 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total value of $819,158.64. Following the completion of the sale, the vice president owned 14,604 shares in the company, valued at approximately $2,463,548.76. The trade was a 24.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,830 shares of company stock worth $3,905,003 in the last three months. Corporate insiders own 2.10% of the company’s stock.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $167.58 on Tuesday. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of 142.02, a PEG ratio of 2.12 and a beta of 0.75. The firm’s 50-day moving average is $167.74 and its 200 day moving average is $144.99.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Research analysts predict that ICU Medical, Inc. will post 7.19 EPS for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.